BibTex RIS Cite

Araştırma Makalesi Adıyaman Hastanelerine Başvuran KOAH’lı Hastalarda Antioksidan Sistem Enzim Aktivitelerinin İncelenmesi

Year 2015, Volume: 1 Issue: 1, 23 - 28, 15.04.2015

Abstract

Amaç: Adıyaman’da yaşayan kronik obstrüktif akciğer hastalığı
(KOAH) olan hastalarda antioksidan sistem enzimlerinden
süperoksit dismutaz (SOD), katalaz (CAT), paraoksonaz 1 (PON
1) enzim aktivitelerinin lipid peroksidasyonu ürünlerinden
malondialdehid (MDA) düzeyleri incelendi. Bölgedeki ilk çalışma
oldu.
Yöntem: Adıyaman Eğitim ve Araştırma hastanelerine başvuran
olgulardan alınan kan örneklerinde lipid peroksidasyonunu
belirlemek için malondialdehit (MDA) düzeylerine, antioksidan
düzeylerini belirlemek için ise katalaz, paraoksonaz 1 (PON1) ve
süperoksitdismutaz (SOD) aktivitelerine bakıldı. EDTA’lı tüplere
alınan venöz kan örnekleri 10 dakika 3000 rpm’de santrifüj
edilerek plazmaları ayrıldı ve analiz yapılana dek -20oC’de
saklandı. SOD, MDA PON1 ve CAT değerleri bakımından
kontrol, KOAH grupları arasındaki istatistiksel farklılıkların test
edilmesinde ANOVA ve alt grup karşılaştırmalarında LSD çoklu
karşılaştırma testleri kullanıldı. Tanıtıcı istatistik olarak ortalama ±
standart sapma değerleri verildi ve değişkenler için Error bar
grafikleri çizildi.
Bulgular: Elde edilen bulgulara göre MDA düzeyleri kontrol
grubunda 6,88 ± 2,14nmol/L iken, KOAH’lı hastalarda 12,88 ±
6,01 nmol/L olarak bulundu. Plazma katalaz seviyeleri kontrol
grubunda 48,23 ± 18,86 U/L iken, KOAH’lı hastalarda 17,09 ±
8,82 U/L olarak tespit edildi. Plazma PON aktiviteleri kontrol
grubunda 45,89 ± 16,46 U/L iken, KOAH’lı hastalarda 28,52 ±
14,85U/L olarak saptandı. Plazma SOD aktiviteleri kontrol
grubunda 60,36 ± 20,29U/L iken, KOAH’lı hastalarda 33,44 ±
12,32U/L olarak ölçüldü. KOAH olgularının verileri, kontrol
grubunun verileri ile karşılaştırıldığında plazma MDA
konsantrasyonunda istatistiksel olarak anlamlı bir artışın (p

References

  • Kocabaş A, Yıldırım N, Gürgün A, Saryal S, Köktürk N, Yarkın T, Kıyan E, Kunt Uzaslan E, Sevinç C, Çöplü L, Sayıner A, Günen H, Karakurt S, Ergün P, Erdinç M, Şen E, Umut S, Yılmaz V, Çımrın AH, Demir T. KOAH Epidemiyolojisi, Yükü ve Ulusal Kontrol Programı. Editörler: Sema Umut, Sevgi Bartu Saryal. Türk Toraks Derneği Kronik Obstrüktif Akciğer Hastalığı Tanı Ve Tedavi Uzlaşı Raporu. Ankara. Görsel Dizayn Ofset Matbaacılık Tic. Ltd. Şti. 2010. Sayfa: 7-12.
  • Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease Eur Respir J 2003; 21:347-60.
  • Günen H, Hacıevliyagil S, Yetkin O, Gülbaş G, Mutlu LC, Pehlivan E. Prevalence of COPD: first epidemiologica lstudy of a large region in Turkey. Eur J Intern Med 2008; 19: 499504.
  • Uzun K. Oxidative stress in smokers and COPD. T Klin J Med Sci 1999; 19(2): 123-129.
  • Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C- reactive protein and mortality in mild to modorate chronic obstructive pulmonary disease. Thorax 2006; 61: 84953.
  • Yin P, Jiang CQ, Cheng KK, Lam TH, Lam KH, Miller MR, Zhang WS, Thomas GN, Adab P. Passive Smoking Exposure and risk of COPD among adults in China. The Guangzhou Biobank Cohort Study. Lancet 2007; 370: 751-757.
  • Tzortzaki EG, Stafakas NM. Genetic susceptibility to chronic obstructive pulmonary disease. Eur Respir Mon 2006; 38: 8499.
  • Buist AS. Introduction. Proc Am Thorac Soc 2008; 5:796-9
  • World Health Organization. Global Burden Disease. http//www.whoint/healthinfo/global_burden_disease/GBD_rep ort_2004update_full.pdf. Erişim tarihi: 05.05.2015.
  • Global Initiative for Obstructive Lung Disease. Global Strategy for the diagnosis, management and preventation of choronic obstructive pulmonary disease. GOLD 2009. www.goldcopd.org. Erişim tarihi: 05.05.2015.
  • M Siedlinski, CC vanDiemen, DS Postman JM, Vonkand HM. Boezen. Superoxide dismutases, lung function and bronchial responsiveness in a general population. Eur Respir J 2009; 33: 986–992.
  • Mac Neeand Rahman I. Oxidants and antioksidants as thrapeuatic targets in chronic obstructive pulmonary disease. Am. J. Respir. Crit Care Med 1999; 160: 58S-65S.
  • Yagi K. Simple procedure for specific enzyme of lipid hydroperoxides in serum or plasma. Methods Mol Biol 1998; 108:107–110.
  • Aebi, H. Catalase in vitro. Methods Enzymol 1984; 105: 121126.
  • Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
  • Sun Y, Oberley LW, YingL. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34: 497-500.
  • Halliwell B. Antioxidants in human health and disease. Annu Rev Nutr 1996; 16: 33–50.
  • Rahman I, MacNee W. Role of transcription factors in inflammatory lung diseases. Thorax 1998; 53: 601–612.
  • Agacdiken A, Basyigit I, Ozden M, Yildiz F, Ural D, Maral H, Boyaci H, Ilgazli A, Komsuoglu B. Theeffects of antioxidants on exercise-induced lipid peroxidation in patients with COPD. Respirology 2004; 9(1): 38-42.
  • Isik B, Ceylan A, Isik R. Oxidative Stress in Smokers and Non-smokers. Inhal Toxicol 2007; 19(9): 767–769.
  • Tug T, Karatas F, Terzi SM. Antioxidant vitamins (A, C and E) and malondialdehyde levels in acute exacerbation and stable periods of patients with chronic obstructive pulmonary disease. Clin Invest Med 2004; 27(3): 123-8.
  • Nishio E, Watanabe Y. 1997. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 1997; 236(2): 28993.
  • Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98(5): 883-5.
  • Juretić D, Tadijanović M, Rekić B, Simeon-Rudolf V, Reiner E, Baricić M. Serum paraoxonase activities in hemodialyzed uremic patients: cohortstudy. Croat Med J 2001; 42: 146-50.
  • Li WF, Furlong CE, Costa LG. Paraoxonase protects against chlorpyrifostoxicity in mice. Toxicol Lett 1995; 76:219-26.
  • La Du BN, Adkins S, Kuo CL, Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 1993; 87(1-): 25-34.
  • La Du BN. Structural and functional diversity of paraoxonases. Nat Med 1996; 2: 1186.
  • Taşkiran P, Cam SF, Sekuri C, Tüzün N, Alioğlu E, Altintaş N, Berdeli A. The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Turk Kardiyol Dern Ars 2009; 37;(7): 473-478.
  • Mak JC, Ho SP, Yu WC, Choo KL, Chu CM, Yew WW, Lam WK, Chan-Yeung M. Polymorphisms and functional activity in superoxide dismutase and catalase genes in smokers with COPD. Eur Respir J 2007; 30(4): 684–690.
  • İlieva V, Nikolava G, Gadjeva V. Lipid peroxidation and catalase activities in patients with choronic obstructive pulmanary diseases: A comparative study with other pulmonary diseases. Trakia J of Sciences 2014; No: 2, pp;177-181.
  • Kohei KAKU. Pathophysiology of Type 2 Diabetes and Its Treatment Policy. JMAJ 2010; 53(1): 41–46.
Year 2015, Volume: 1 Issue: 1, 23 - 28, 15.04.2015

Abstract

References

  • Kocabaş A, Yıldırım N, Gürgün A, Saryal S, Köktürk N, Yarkın T, Kıyan E, Kunt Uzaslan E, Sevinç C, Çöplü L, Sayıner A, Günen H, Karakurt S, Ergün P, Erdinç M, Şen E, Umut S, Yılmaz V, Çımrın AH, Demir T. KOAH Epidemiyolojisi, Yükü ve Ulusal Kontrol Programı. Editörler: Sema Umut, Sevgi Bartu Saryal. Türk Toraks Derneği Kronik Obstrüktif Akciğer Hastalığı Tanı Ve Tedavi Uzlaşı Raporu. Ankara. Görsel Dizayn Ofset Matbaacılık Tic. Ltd. Şti. 2010. Sayfa: 7-12.
  • Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease Eur Respir J 2003; 21:347-60.
  • Günen H, Hacıevliyagil S, Yetkin O, Gülbaş G, Mutlu LC, Pehlivan E. Prevalence of COPD: first epidemiologica lstudy of a large region in Turkey. Eur J Intern Med 2008; 19: 499504.
  • Uzun K. Oxidative stress in smokers and COPD. T Klin J Med Sci 1999; 19(2): 123-129.
  • Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C- reactive protein and mortality in mild to modorate chronic obstructive pulmonary disease. Thorax 2006; 61: 84953.
  • Yin P, Jiang CQ, Cheng KK, Lam TH, Lam KH, Miller MR, Zhang WS, Thomas GN, Adab P. Passive Smoking Exposure and risk of COPD among adults in China. The Guangzhou Biobank Cohort Study. Lancet 2007; 370: 751-757.
  • Tzortzaki EG, Stafakas NM. Genetic susceptibility to chronic obstructive pulmonary disease. Eur Respir Mon 2006; 38: 8499.
  • Buist AS. Introduction. Proc Am Thorac Soc 2008; 5:796-9
  • World Health Organization. Global Burden Disease. http//www.whoint/healthinfo/global_burden_disease/GBD_rep ort_2004update_full.pdf. Erişim tarihi: 05.05.2015.
  • Global Initiative for Obstructive Lung Disease. Global Strategy for the diagnosis, management and preventation of choronic obstructive pulmonary disease. GOLD 2009. www.goldcopd.org. Erişim tarihi: 05.05.2015.
  • M Siedlinski, CC vanDiemen, DS Postman JM, Vonkand HM. Boezen. Superoxide dismutases, lung function and bronchial responsiveness in a general population. Eur Respir J 2009; 33: 986–992.
  • Mac Neeand Rahman I. Oxidants and antioksidants as thrapeuatic targets in chronic obstructive pulmonary disease. Am. J. Respir. Crit Care Med 1999; 160: 58S-65S.
  • Yagi K. Simple procedure for specific enzyme of lipid hydroperoxides in serum or plasma. Methods Mol Biol 1998; 108:107–110.
  • Aebi, H. Catalase in vitro. Methods Enzymol 1984; 105: 121126.
  • Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
  • Sun Y, Oberley LW, YingL. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34: 497-500.
  • Halliwell B. Antioxidants in human health and disease. Annu Rev Nutr 1996; 16: 33–50.
  • Rahman I, MacNee W. Role of transcription factors in inflammatory lung diseases. Thorax 1998; 53: 601–612.
  • Agacdiken A, Basyigit I, Ozden M, Yildiz F, Ural D, Maral H, Boyaci H, Ilgazli A, Komsuoglu B. Theeffects of antioxidants on exercise-induced lipid peroxidation in patients with COPD. Respirology 2004; 9(1): 38-42.
  • Isik B, Ceylan A, Isik R. Oxidative Stress in Smokers and Non-smokers. Inhal Toxicol 2007; 19(9): 767–769.
  • Tug T, Karatas F, Terzi SM. Antioxidant vitamins (A, C and E) and malondialdehyde levels in acute exacerbation and stable periods of patients with chronic obstructive pulmonary disease. Clin Invest Med 2004; 27(3): 123-8.
  • Nishio E, Watanabe Y. 1997. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 1997; 236(2): 28993.
  • Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98(5): 883-5.
  • Juretić D, Tadijanović M, Rekić B, Simeon-Rudolf V, Reiner E, Baricić M. Serum paraoxonase activities in hemodialyzed uremic patients: cohortstudy. Croat Med J 2001; 42: 146-50.
  • Li WF, Furlong CE, Costa LG. Paraoxonase protects against chlorpyrifostoxicity in mice. Toxicol Lett 1995; 76:219-26.
  • La Du BN, Adkins S, Kuo CL, Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 1993; 87(1-): 25-34.
  • La Du BN. Structural and functional diversity of paraoxonases. Nat Med 1996; 2: 1186.
  • Taşkiran P, Cam SF, Sekuri C, Tüzün N, Alioğlu E, Altintaş N, Berdeli A. The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Turk Kardiyol Dern Ars 2009; 37;(7): 473-478.
  • Mak JC, Ho SP, Yu WC, Choo KL, Chu CM, Yew WW, Lam WK, Chan-Yeung M. Polymorphisms and functional activity in superoxide dismutase and catalase genes in smokers with COPD. Eur Respir J 2007; 30(4): 684–690.
  • İlieva V, Nikolava G, Gadjeva V. Lipid peroxidation and catalase activities in patients with choronic obstructive pulmanary diseases: A comparative study with other pulmonary diseases. Trakia J of Sciences 2014; No: 2, pp;177-181.
  • Kohei KAKU. Pathophysiology of Type 2 Diabetes and Its Treatment Policy. JMAJ 2010; 53(1): 41–46.
There are 31 citations in total.

Details

Primary Language Turkish
Journal Section Research Article
Authors

Devrim Taşkın This is me

Muhittin Öndeci

Serap Yalın

Füsun Fakıoğlu This is me

Ülkü Çömelekoğlu

Sedat Yılmaz This is me

Abdullah Arpacı This is me

Publication Date April 15, 2015
Submission Date March 14, 2016
Published in Issue Year 2015 Volume: 1 Issue: 1

Cite

AMA Taşkın D, Öndeci M, Yalın S, Fakıoğlu F, Çömelekoğlu Ü, Yılmaz S, Arpacı A. Araştırma Makalesi Adıyaman Hastanelerine Başvuran KOAH’lı Hastalarda Antioksidan Sistem Enzim Aktivitelerinin İncelenmesi. ADYÜ Sağlık Bilimleri Derg. April 2015;1(1):23-28.